LXRXHIGH SIGNALFINANCIAL10-K

Lexicon Pharmaceuticals shows dramatic operational improvement with substantially reduced losses and debt while revenue grew meaningfully, though cash position remains a concern.

The company has achieved a substantial turnaround in operational efficiency, cutting losses by roughly three-quarters while growing revenue meaningfully. However, the significant decline in cash reserves combined with ongoing negative cash flow raises questions about funding sustainability for continued operations and drug development programs.

Comparing 2026-03-05 vs 2025-03-07View on EDGAR →
FINANCIAL ANALYSIS

LXRX demonstrated marked financial improvement with operating losses and net losses both substantially reduced while revenue grew meaningfully year-over-year. The company dramatically cut total debt by over 80% and reduced SG&A expenses by nearly three-quarters, indicating successful cost management. However, current assets and cash declined significantly, and the company continues burning cash operationally, creating potential liquidity concerns despite the operational improvements.

FINANCIAL STATEMENT CHANGES
Total Debt
Balance Sheet
-80.5%
$248.6M→$48.6M

Debt reduced 80.5% — deleveraging strengthens balance sheet and reduces financial risk.

Operating Income
P&L
+75.2%
-$197.1M→-$48.9M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+74.9%
-$200.4M→-$50.3M

Net income grew 74.9% — bottom-line growth signals improving overall business health.

SG&A Expense
P&L
-73.9%
$143.1M→$37.3M

SG&A reduced 73.9% — improved cost efficiency or headcount reduction improving operating margins.

Operating Cash Flow
Cash Flow
+62%
-$178.8M→-$67.9M

Operating cash flow surged 62% — exceptional cash generation, highest quality earnings signal.

Revenue
P&L
+60.2%
$31.1M→$49.8M

Strong top-line growth of 60.2% — accelerating demand or successful expansion into new markets.

Current Assets
Balance Sheet
-58.6%
$246.2M→$101.9M

Current assets declined 58.6% — monitor working capital adequacy and short-term liquidity.

Current Liabilities
Balance Sheet
-53.9%
$45.2M→$20.9M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-49.2%
$152.5M→$77.4M

Liabilities reduced 49.2% — deleveraging improves balance sheet strength and financial flexibility.

Cash & Equivalents
Balance Sheet
-48.5%
$66.7M→$34.3M

Cash declined 48.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

LANGUAGE CHANGES
NEW — 2026-03-05
PRIOR — 2025-03-07
ADDED
As of March 4, 2026, 423,680,611 shares of common stock were outstanding.
Management s Discussion and Analysis of Financial Condition and Results of Operations 37 7A.
Form 10-K Summary 49 Signatures 50 The Lexicon name and logo, INPEFA and ZYNQUISTA are registered trademarks of Lexicon Pharmaceuticals, Inc.
We are devoting most of our resources to the research and development of our most advanced drug candidates and the commercialization of our approved drug, INPEFA (sotagliflozin): We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for hypertrophic cardiomyopathy, or HCM, and are conducting the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication.
Food and Drug Administration, or FDA, issued complete response letters regarding our New Drug Application, or NDA, for ZYNQUISTA in type 1 diabetes in March 2019 and December 2024.
The FDA has separately provided feedback that a third-party-funded, investigator-initiated study of sotagliflozin appears to be of adequate design and employs sufficient data collection methods to provide viable evidence of the incidence of diabetic ketoacidosis, or DKA, with adequate safety data, prior to its completion, to support review of a resubmission of the NDA.
We are preparing to potentially resubmit the NDA for ZYNQUISTA in type 1 diabetes if supported by patient exposure and safety data from such study.
We are developing pilavapadin, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.
We have completed two Phase 2 clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain, or DPNP.
We have reported results from our PROGRESS Phase 2b clinical trial of pilavapadin in DPNP, which demonstrated clear evidence of effect at the 10 mg dose, and positive results from our RELIEF-DPN-1 Phase 2a clinical trial of pilavapadin in DPNP.
REMOVED
As of February 28, 2025, 361,492,295 shares of common stock were outstanding.
Management s Discussion and Analysis of Financial Condition and Results of Operations 38 7A.
Form 10-K Summary 50 Signatures 51 The Lexicon name and logo and INPEFA are registered trademarks of Lexicon Pharmaceuticals, Inc.
We are devoting most of our resources to the research and development of our most advanced drug candidates and the commercialization of our approved drug, INPEFA (sotagliflozin): We are developing pilavapadin (LX 9211), an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.
We have completed three Phase 2 clinical trials ev aluating the safety and tolerability of pilavapadin and its effects on DPNP and neuropathic pain.
We have reported top-line results from our Phase 2b clinical trial of pilavapadin in diabetic peripheral neuropathic pain, or DPNP, which demonstrated clear evidence of effect at the 10 mg dose and have received Fast Track designation from the U.S.
Food and Drug Administration, or FDA, for development of pilavapadin in that indication.
We have also reported positive results from a Phase 2a clinical trial of pilavapadin in DPNP and results from a separate Phase 2a clinical trial of pilavapadin in post-herpetic neuralgia which also demonstrated evidence of effect.
We are developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and are conducting preclinical development of LX9851 in preparation for filing an investigational new drug application, or IND, with the FDA.
We are commercializing INPEFA (sotagliflozin), an orally-delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, or CKD, and other cardiovascular risk factors.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →